AI-assisted, human-published
03/22/2024 /M & A
Gilead Sciences Completes Acquisition of CymaBay Therapeutics for $4.3 Billion
Gilead Sciences announced it has finalized the acquisition of CymaBay Therapeutics, integrating seladelpar into its liver portfolio, and reducing 2024 EPS by approximately $3.10 - $3.20.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com